These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32306296)

  • 1. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
    Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA
    Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J; Meloni A; Han J
    Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
    van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
    Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
    Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
    Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
    Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
    Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
    Grimm M; Li Y; Brunell SC; Blase E
    Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.
    Ji L; Onishi Y; Ahn CW; Agarwal P; Chou CW; Haber H; Guerrettaz K; Boardman MK
    J Diabetes Investig; 2013 Jan; 4(1):53-61. PubMed ID: 24843631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
    Bethel MA; Mentz RJ; Merrill P; Buse JB; Chan JC; Goodman SG; Iqbal N; Jakuboniene N; Katona B; Lokhnygina Y; Lopes RD; Maggioni AP; Ohman P; Tankova T; Bakris GL; Hernandez AF; Holman RR
    Diabetes Care; 2020 Feb; 43(2):446-452. PubMed ID: 31757838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.
    Stolar MW; Grimm M; Chen S
    Diabetes Metab Syndr Obes; 2013; 6():435-44. PubMed ID: 24285927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
    van der Aart-van der Beek AB; Clegg LE; Penland RC; Boulton DW; Sjöström CD; Mentz RJ; Holman RR; Heerspink HJL
    Diabetes Obes Metab; 2020 Dec; 22(12):2493-2498. PubMed ID: 32803900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
    Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
    Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
    Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
    Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
    Paul SK; Maggs D; Klein K; Best JH
    J Diabetes; 2015 Jan; 7(1):60-7. PubMed ID: 25168883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of metformin monotherapy in US veterans with type 2 diabetes and preexisting chronic kidney disease stage 3.
    Gosmanov AR; Gemoets DE; Kaminsky LS; Kovesdy CP; Gosmanova EO
    Diabetes Obes Metab; 2021 Aug; 23(8):1879-1885. PubMed ID: 33908689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.